Efficacy and Safety of Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in the Geriatric Adult with Renal Impairment

被引：0
|
作者：
Martorell, C. [3 ]
Ward, D. [2 ]
Short, W. S. [4 ]
Ramgopal, M. [5 ]
Das, M. [1 ]
Nguyen-Cleary, T. [1 ]
Shave, A. [1 ]
McCallister, S. [1 ]
机构：
[1] Gilead Sci, Foster City, CA USA
[2] DuPont Circle Phys, Washington, DC USA
[3] Res Inst, Springfield, MA USA
[4] Univ Penn, Philadelphia, PA 19104 USA
[5] Midway Immunol & Res Ctr, Ft Pierce, FL USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2017年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
C86
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [31] Effectiveness, persistence and safety in treatment-naive and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)-12-month evaluation of the French TARANIS cohort
    Meynard, J-L
    Duvivier, C.
    Molina, J-M
    Ajana, F.
    Pichancourt, G.
    Morlat, P.
    Revest, M.
    Poizot-Martin, I.
    Hocqueloux, L.
    Janssen, C.
    Genet, P.
    Katlama, C.
    Leclercq, P.
    Haubrich, R.
    Ramroth, H.
    Durand, F.
    Sahali, S.
    [J]. HIV MEDICINE, 2019, 20 : 59 - 60
  • [32] HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
    Marianne Harris
    Bruce Ganase
    Birgit Watson
    P. Richard Harrigan
    Julio S. G. Montaner
    Mark W. Hull
    [J]. AIDS Research and Therapy, 14
  • [33] HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
    Harris, Marianne
    Ganase, Bruce
    Watson, Birgit
    Harrigan, P. Richard
    Montaner, Julio S. G.
    Hull, Mark W.
    [J]. AIDS RESEARCH AND THERAPY, 2017, 14 : 1 - 9
  • [34] Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials
    Kim, Yeon-Sook
    Oka, Shinichi
    Chetchotisakd, Ploenchan
    Clarke, Amanda
    Supparatpinyo, Khuanchai
    Avihingsanon, Anchalee
    Ratanasuwan, Winai
    Kiertiburanakul, Sasisopin
    Ruxrungtham, Kiat
    Yang, SangYoun
    Guo, Susan
    Liu, YaPei
    Das, Moupali
    Tran, Do
    McColl, Damian
    Corales, Roberto
    Nguyen, Chris
    Piontkowsky, David
    [J]. HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (03) : 73 - 81
  • [35] Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial
    Perez Valero, I.
    Cabello, A.
    Ryan, P.
    de la Fuente Moral, S.
    Santos, I.
    Vivancos, M. J.
    Gorgolas, M.
    Cuevas, G.
    Diaz De Santiago, A.
    Garcia-Fraile, L.
    Bernardino, J. I.
    Valencia, E.
    Montes, M.
    Rua, G.
    Yllescas, M.
    Gonzalez, A.
    [J]. HIV MEDICINE, 2019, 20 : 90 - 91
  • [36] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV
    Hill, L.
    Momper, J.
    Abulhosn, K.
    Ballard, C.
    Young, M.
    [J]. HIV MEDICINE, 2019, 20 : 81 - 81
  • [37] Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
    Kityo, C.
    Hagins, D.
    Koenig, E.
    Avihingsanon, A.
    Chetchotisakd, P.
    Supparatpinyo, K.
    Gankina, N.
    Pokrovsky, V.
    Voronin, E.
    Stephens, J. L.
    DeJesus, E.
    Wang, H.
    Acosta, R.
    Brainard, D.
    Martin, H.
    Makadzange, T. A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 4 - 4
  • [38] Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen
    Rizzardini, Giuliano
    Gori, Andrea
    Miralles, Celia
    Olalla, Julian
    Molina, Jean-Michel
    Raffi, Francois
    Kumar, Princy
    Antinori, Andrea
    Ramgopal, Moti
    Stellbrink, Hans-Jurgen
    Das, Moupali
    Chu, Hoa
    Ram, Renee
    Garner, Will
    Shao, Yongwu
    Chuck, Susan K.
    Piontkowsky, David
    Haubrich, Richard H.
    [J]. AIDS, 2019, 33 (10) : 1583 - 1593
  • [39] Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60
    Maggiolo, F.
    Rizzardini, G.
    Raffi, F.
    Pulido, F.
    Mateo Garcia, G.
    Molina, J.
    Ong, E.
    Shao, Y.
    Corales, R.
    McNicholl, I.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [40] Gastrointestinal (GI) adverse events with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) through Week 96: an EMERALD post-hoc analysis
    Dunn, K.
    Baugh, B.
    Bejou, N.
    Luo, D.
    Campbell, J.
    Seyedkazemi, S.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 81 - 82
12345